Novo Nordisk A/S
As of Oct 22, 2026, Novo Nordisk is in Stage 4, the downtrend phase, now in week 3 (since Oct 2, 2026). It closed at $39.43, 35.3% below its 52-week high and below its 200-day average, which is falling.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NVO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NVO among Drug Manufacturers - General16th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …16 | NVO | Stage 4 · wk 3 | 37 | +3.3% |
Novo Nordisk: quick answers
What stage is Novo Nordisk in?
As of Oct 22, 2026, Novo Nordisk (NVO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Novo Nordisk in an uptrend?
No. Novo Nordisk is in a Stage 4 downtrend. It trades 10.1% below its 200-day average, which is falling.
How far is Novo Nordisk from its 52-week high?
Novo Nordisk closed at $39.43 on Oct 22, 2026, 35.3% below its 52-week high of $60.94. Its 52-week low is $34.33.
How has Novo Nordisk performed over the past year?
As of Oct 22, 2026, Novo Nordisk is down 24.4% over the past year and down 21.0% so far in 2026.
Which sector and industry is Novo Nordisk in?
Novo Nordisk is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.